Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer
ConditionBreast Neoplasms
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorAstraZeneca
About this trial
It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.
Eligibility criteria
Qualifiers
female patients,
aged 18 years or older,
identified as high genetic risk by breast surgeons,
referred to a geneticist, and
Disqualifiers
male patients,
absence of complete information in the medical records,
patients unaware of their biological family history, and
patients who do not agree to participate in the study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov